Literature DB >> 20807028

Bloodstream yeast infections in a university hospital in Northeast Turkey: a 4-year survey.

Faruk Aydin1, Gulcin Bayramoglu, Necla Cebeci Guler, Nese Kaklikkaya, Ilknur Tosun.   

Abstract

This study presents data on species distribution and antifungal susceptibility profiles of Candida bloodstream isolates obtained from a Turkish Tertiary Care Hospital during a 4-year period. All hospitalized patients who had ≥ 1 blood culture positive for yeast during their hospital stay from January 2005 through 2009 were included in this study. All isolates were identified to species level using CHROMagar and ID 32 C. Fluconazole and voriconazole antifungal susceptibility testing was performed using the disk diffusion method according to CLSI M44-A. In vitro activity of amphotericin B was determined by the Etest. Of all 166 yeast isolates, C. albicans was the dominant species (34.3%), followed by Candida parapsilosis (28.9%) and C. tropicalis (8.4%). All of the 48 C. parapsilosis strains were identified as C. parapsilosis sensu stricto. Resistance to fluconazole was more common among C. krusei isolates. Voriconazole resistance was absent. One C. lusitaniae strain showed a high amphotericin MIC (4 μg/ml). Our survey indicated an increase of some non-C. albicans Candida species in our hospital while antifungal resistance was uncommon.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20807028     DOI: 10.3109/13693786.2010.512023

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  8 in total

1.  Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates.

Authors:  Dilek Yesim Metin; Suleyha Hilmioglu-Polat; Pinar Samlioglu; Biray Doganay-Oflazoglu; Ramazan Inci; Emel Tumbay
Journal:  Mycopathologia       Date:  2011-03-20       Impact factor: 2.574

2.  Hemolytic factor production by clinical isolates of Candida species.

Authors:  Daniel Favero; Luciana Furlaneto-Maia; Emanuele J G França; Helena Peggau Góes; Marcia Cristina Furlaneto
Journal:  Curr Microbiol       Date:  2013-09-19       Impact factor: 2.188

3.  In vitro susceptibility of Candida species to four antifungal agents assessed by the reference broth microdilution method.

Authors:  Fahriye Eksi; Efgan Dogan Gayyurhan; Iclal Balci
Journal:  ScientificWorldJournal       Date:  2013-10-22

4.  Molecular Identification and Echinocandin Susceptibility of Candida parapsilosis Complex Bloodstream Isolates in Italy, 2007-2014.

Authors:  Grazia Lovero; Elisa Borghi; Stella Balbino; Daniela Cirasola; Osvalda De Giglio; Federica Perdoni; Giuseppina Caggiano; Giulia Morace; Maria Teresa Montagna
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

5.  Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.

Authors:  Hatice Turk Dagi; Duygu Findik; Cigdem Senkeles; Ugur Arslan
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-05-31       Impact factor: 3.944

6.  Bacterial and fungal profile, drug resistance pattern and associated factors of isolates recovered from blood samples of patients referred to Ethiopian Public Health Institute: cross-sectional study.

Authors:  Etsehiwot Adamu Tsegaye; Dejenie Shiferaw Teklu; Zelalem Tazu Bonger; Abebe Aseffa Negeri; Tesfaye Legesse Bedada; Adane Bitew
Journal:  BMC Infect Dis       Date:  2021-11-29       Impact factor: 3.090

7.  Characteristics of Biofilms Formed by C. parapsilosis Causing an Outbreak in a Neonatal Intensive Care Unit.

Authors:  Atsushi Miyake; Kenji Gotoh; Jun Iwahashi; Akinobu Togo; Rie Horita; Miho Miura; Masahiro Kinoshita; Keisuke Ohta; Yushiro Yamashita; Hiroshi Watanabe
Journal:  J Fungi (Basel)       Date:  2022-07-01

8.  High Recovery Rate of Non-albicans Candida Species Isolated From Burn Patients With Candidemia in Iran.

Authors:  Nazanin Lotfi; Tahereh Shokohi; Seyed Zahra Nouranibaladezaei; Ayatollah Nasrolahi Omran; Nahid Kondori
Journal:  Jundishapur J Microbiol       Date:  2015-10-24       Impact factor: 0.747

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.